CRMD

CorMedix Inc. (CRMD) | Rumor.io

CorMedix

CRMD

Attention (50-day avg)0%

Attention rank (50-day avg)#1,027

Bullish sentiment (50-day avg)71%

Price to earnings ratio3.6

Market capitalization615M

Earnings per share2.18

Dividend yield (TTM)—

Revenue (annual)311.7M

Net income (annual)163.1M

Social

What share of all stock conversation is about CRMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.02

Sep 24

Oppenheimer initiated coverage on CorMedix Inc. with an Outperform rating and a $15.00 price target, citing strong underlying demand for the company's lead product, DefenCath, and growing availability across large dialysis organizations.
CorMedix estimates that the U.S. market opportunity for REZZAYO in prophylaxis exceeds $2 billion, with long exclusivity windows benefiting from orphan drug exclusivity through 2035 and patent coverage extending to 2038 in the U.S.
Institutional investors, including BlackRock Inc., Deerfield Management Company, and the Bank of New York Mellon Corp, have opened or increased positions in CorMedix, with 68 institutional managers adding to their positions and 27 opening new ones in recent reporting cycles.

Generated by AI

Sentiment

Of the messages about CRMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% -33.33	70% +5.29	70.23% -0.94	65.93% -16.05
Bearish	33.33% +33.33	30% -5.29	29.77% +0.94	34.07% +16.05

Bullish· Aug 14

The company has a strong revenue stream with DefenCath, which is already generating meaningful revenue and has raised guidance for FY2026.
Institutional investment continues to increase, with the company's guidance for revenue of $345 million and EBITDA of $140 million, making it a compelling buy opportunity.
The stock has a high short interest of 20%+, which could lead to a potential squeeze and a significant increase in price, making it a high-risk, high-reward investment.

Bearish· Aug 14

The asset's price has not increased despite positive earnings, with one post stating it's "like a dinner bell for shorts" and another noting it's dropped 22% despite "good news".
The asset's price is heavily influenced by short selling, with one post mentioning "700 and 1100 front and center in the thievery" and another stating "the 700 bass turd is in full attack mode".
The asset's price is highly volatile, with one post stating it's "easy to borrow, despite it being over 70% IO" and another noting it's dropped 22% despite "catalysts ahead" and "22% short interest".

Generated by AI

Topics

Of the messages about CRMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.43%	86.21%	9.88%
Technical Analysis	—	14.29%	6.9%	2.9%
Earnings	—	0%	0%	3.89%
Analysts	—	14.29%	6.9%	44.26%
Controversies	—	0%	0%	0.13%
Macro	—	0%	0%	38.94%

Earnings· Nov 12

CorMedix Inc. ($CRMD) reported Q3 2025 earnings with record revenue of $104.3M and net income of $108.6M, exceeding estimates.
The company raised its full-year 2025 pro forma revenue guidance to $390-$410M and adjusted EBITDA to $220-$240M.
Strong demand for DefenCath and the Melinta acquisition drove the revenue surge, with synergy capture projected at $30M before year-end.

Analysts· Feb 2

CorMedix Inc. ($CRMD) price target raised to $35 from $20 at Truist Securities, with analyst Joon Lee maintaining a Buy rating and citing potential cost savings of up to $1.2B in hemodialysis.
The analyst states that the opportunity around CorMedix's Defencath catheter lock solution in hemodialysis may be larger than previously modeled, and could be a strong motivator for the CMS to include Defencath under TDAPA coverage with favorable pricing.
100% of analysts covering CorMedix Inc. ($CRMD) have a Buy consensus, indicating high confidence in the stock's potential.

Announcements· Jan 8

CorMedix Inc. ($CRMD) announced the appointment of Mike Seckler as EVP & Chief Commercial Officer, bringing experience in hematology and oncology.
The company reported preliminary Q4 2025 net revenue of $127 million and full-year 2025 revenue of $310 million, with pro forma net revenue of $400 million.
CorMedix guided FY 2026 revenue to $300M-$320M, with $150M-$170M from DefenCath, and adjusted EBITDA of $100-$125M, with a strong cash position and multiple Phase 3 catalysts.

Technical Analysis· Feb 11

CRMD may find support around $13.50-$13.60, which is its February 2019 peak.
The stock has reached its strongest resistance since 2014, potentially breaking through to use it as support.
A pullback after a massive move is considered healthy, with lower volume on down days, and a potential opportunity to add to a trading position if it spikes down to $13 again.

Generated by AI

Community

Of the messages about CRMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	76.47%	89.58%	86.24%	80.63%
Newcomers	23.53%	10.42%	13.76%	19.37%

Regulars· Sep 23

Regulars are focusing on the recent Oppenheimer initiation with an Outperform rating and $15 price target, highlighting the company's resilient utilization, expanded access, and diversified portfolio as key growth drivers.
The upgrade to $15 after a beat on earnings and the company's market cap reaching $600 million has sparked discussion among regulars, with some questioning the valuation and others seeing significant upside potential.
The Zacks upgrade to "Buy" has also been highlighted, citing the company's strong earnings estimate revisions, consecutive earnings beats, and revenue growth outperformance, which have led to a positive earnings surprise and a significant increase in institutional ownership.

Newcomers· Aug 19

Newcomers to the stock are excited about its potential, with one user wondering what's so good about the stock and ready to invest.
The stock's price has been holding above $8.30, with a significant sell wall at that price being abandoned, and institutional investors are waiting for more opportunities to buy.
There are rumors of a possible cup and handle pattern forming, with a potential target price of $9.20, and some users are speculating about the stock's future price movements.

Generated by AI

On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]

22d agoYahoo Finance

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

22d agoYahoo Finance

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

28d agofinance.yahoo.com

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

29d agoYahoo Finance

Also Discussed

Investors talking about CRMD also mention

#	Name	Attention
1	IGC Pharma Inc.IGC	0.01%+0
2	TRVN - Trevena, Inc.	——
3	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
4	Oragenics Inc.OGEN	0%0
5	Talphera, Inc.TLPH	0%0
6	ABIO - ARCA biopharma, Inc.	——
7	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
8	Fresenius Medical Care AG - Depositary ReceiptFMS	0%new
9	NVCN - Neovasc Inc.	——
10	AB Corporate Bond ETFEYEG	0%0

CorMedix Inc.

Healthcare
Biotechnology

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through central venous catheters. The company serves healthcare providers and dialysis settings, where preventing bloodstream infections is a critical part of patient care. CorMedix also operates as a specialty pharmaceutical business with a product portfolio aimed at acute care markets and other medically important settings. Headquartered in Berkeley Heights, New Jersey, CorMedix Inc. plays a targeted role in the healthcare market by addressing complications associated with vascular access and chronic kidney failure treatment.

Website

Location

389 Interpace Pkwy

Parsippany, NJ, 07054

United States

Social

What share of all stock conversation is about CRMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% -0.02

Sep 24

Oppenheimer initiated coverage on CorMedix Inc. with an Outperform rating and a $15.00 price target, citing strong underlying demand for the company's lead product, DefenCath, and growing availability across large dialysis organizations.
CorMedix estimates that the U.S. market opportunity for REZZAYO in prophylaxis exceeds $2 billion, with long exclusivity windows benefiting from orphan drug exclusivity through 2035 and patent coverage extending to 2038 in the U.S.
Institutional investors, including BlackRock Inc., Deerfield Management Company, and the Bank of New York Mellon Corp, have opened or increased positions in CorMedix, with 68 institutional managers adding to their positions and 27 opening new ones in recent reporting cycles.

Generated by AI

Sentiment

Of the messages about CRMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% -33.33	70% +5.29	70.23% -0.94	65.93% -16.05
Bearish	33.33% +33.33	30% -5.29	29.77% +0.94	34.07% +16.05

Bullish· Aug 14

The company has a strong revenue stream with DefenCath, which is already generating meaningful revenue and has raised guidance for FY2026.
Institutional investment continues to increase, with the company's guidance for revenue of $345 million and EBITDA of $140 million, making it a compelling buy opportunity.
The stock has a high short interest of 20%+, which could lead to a potential squeeze and a significant increase in price, making it a high-risk, high-reward investment.

Bearish· Aug 14

The asset's price has not increased despite positive earnings, with one post stating it's "like a dinner bell for shorts" and another noting it's dropped 22% despite "good news".
The asset's price is heavily influenced by short selling, with one post mentioning "700 and 1100 front and center in the thievery" and another stating "the 700 bass turd is in full attack mode".
The asset's price is highly volatile, with one post stating it's "easy to borrow, despite it being over 70% IO" and another noting it's dropped 22% despite "catalysts ahead" and "22% short interest".

Generated by AI

Topics

Of the messages about CRMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.43%	86.21%	9.88%
Technical Analysis	—	14.29%	6.9%	2.9%
Earnings	—	0%	0%	3.89%
Analysts	—	14.29%	6.9%	44.26%
Controversies	—	0%	0%	0.13%
Macro	—	0%	0%	38.94%

Earnings· Nov 12

CorMedix Inc. ($CRMD) reported Q3 2025 earnings with record revenue of $104.3M and net income of $108.6M, exceeding estimates.
The company raised its full-year 2025 pro forma revenue guidance to $390-$410M and adjusted EBITDA to $220-$240M.
Strong demand for DefenCath and the Melinta acquisition drove the revenue surge, with synergy capture projected at $30M before year-end.

Analysts· Feb 2

CorMedix Inc. ($CRMD) price target raised to $35 from $20 at Truist Securities, with analyst Joon Lee maintaining a Buy rating and citing potential cost savings of up to $1.2B in hemodialysis.
The analyst states that the opportunity around CorMedix's Defencath catheter lock solution in hemodialysis may be larger than previously modeled, and could be a strong motivator for the CMS to include Defencath under TDAPA coverage with favorable pricing.
100% of analysts covering CorMedix Inc. ($CRMD) have a Buy consensus, indicating high confidence in the stock's potential.

Announcements· Jan 8

CorMedix Inc. ($CRMD) announced the appointment of Mike Seckler as EVP & Chief Commercial Officer, bringing experience in hematology and oncology.
The company reported preliminary Q4 2025 net revenue of $127 million and full-year 2025 revenue of $310 million, with pro forma net revenue of $400 million.
CorMedix guided FY 2026 revenue to $300M-$320M, with $150M-$170M from DefenCath, and adjusted EBITDA of $100-$125M, with a strong cash position and multiple Phase 3 catalysts.

Technical Analysis· Feb 11

CRMD may find support around $13.50-$13.60, which is its February 2019 peak.
The stock has reached its strongest resistance since 2014, potentially breaking through to use it as support.
A pullback after a massive move is considered healthy, with lower volume on down days, and a potential opportunity to add to a trading position if it spikes down to $13 again.

Generated by AI

Community

Of the messages about CRMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	76.47%	89.58%	86.24%	80.63%
Newcomers	23.53%	10.42%	13.76%	19.37%

Regulars· Sep 23

Regulars are focusing on the recent Oppenheimer initiation with an Outperform rating and $15 price target, highlighting the company's resilient utilization, expanded access, and diversified portfolio as key growth drivers.
The upgrade to $15 after a beat on earnings and the company's market cap reaching $600 million has sparked discussion among regulars, with some questioning the valuation and others seeing significant upside potential.
The Zacks upgrade to "Buy" has also been highlighted, citing the company's strong earnings estimate revisions, consecutive earnings beats, and revenue growth outperformance, which have led to a positive earnings surprise and a significant increase in institutional ownership.

Newcomers· Aug 19

Newcomers to the stock are excited about its potential, with one user wondering what's so good about the stock and ready to invest.
The stock's price has been holding above $8.30, with a significant sell wall at that price being abandoned, and institutional investors are waiting for more opportunities to buy.
There are rumors of a possible cup and handle pattern forming, with a potential target price of $9.20, and some users are speculating about the stock's future price movements.

Generated by AI

CorMedix

Social

Sep 24

Bullish· Aug 14

Bearish· Aug 14

Earnings· Nov 12

Analysts· Feb 2

Announcements· Jan 8

Technical Analysis· Feb 11

Regulars· Sep 23

Newcomers· Aug 19

Oppenheimer initiates CorMedix stock coverage with outperform rating

CorMedix at Wells Fargo 21st annual healthcare conference: growth, risk

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

CorMedix (CRMD) Upgraded to Buy: Here's Why

Also Discussed

CorMedix Inc.

Company Information

Location

Oppenheimer initiates CorMedix stock coverage with outperform rating

CorMedix at Wells Fargo 21st annual healthcare conference: growth, risk

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

CorMedix (CRMD) Upgraded to Buy: Here's Why

Also Discussed

Social

Sep 24

Bullish· Aug 14

Bearish· Aug 14

Earnings· Nov 12

Analysts· Feb 2

Announcements· Jan 8

Technical Analysis· Feb 11

Regulars· Sep 23

Newcomers· Aug 19